340B Unscripted

Ep 62 | Updates from Ongoing 340B Litigation

In this episode, Greg and Rob are joined again by Jeff Davis, healthcare attorney, to catch up on various court action impacting the 340B community. With so many 340B Program elements hung up in litigation, it's challenge to keep tabs on what has been happening. Jeff will recap key appellate court decisions on manufacturer-implemented restrictions of contract pharmacies, discuss the merits of litigation challenging state legislative efforts to protect contract pharmacy provisions, and share opinions on where 340B rebate models may go in the future. They'll also dive in to child site eligibility timing, HRSA-approved manufacturer, audits and recent threats to covered entities who receive in-kind funding. They'll also debate patient definition standards now that we are a year removed from the Genesis case. 
We can't wait to see you at 340B Coalition Winter Conference in San Diego. Catch up with the SpendMend team at Booth #315.   

Ep 61 | What Else is Happening in 340B to Start 2025

In this week’s episode, Greg and Rob catch up on newsworthy developments in the 340B community. They’ll discuss various state and federal legislative developments, they’ll share how recent White House executive orders, including a pause on federal agency communications and grant funding freezes, may be impacting 340B providers, and they’ll offer some commentary on HHS Secretary confirmation hearing debate.
Catch us at the 340B Coalition Winter Conference in San Diego, CA! The SpendMend team will be at Booth 315

Ep 60 | What’s Happening in 340B to Start 2025

In our first episode of 2025, Greg and Rob discuss the latest developments in 340B. They’ll recap HRSA audit trends, discuss how Congressional committee membership seems to be forming, and discuss a variety of 340B provisions being litigated in court.

Ep 59 | Recap of 340B Developments in 2024

In our last episode of 2024, Greg and Rob recap major developments in the 340B space from the last year.  They’ll start with trends in HRSA audit activity, including thoughts on patient definition. They’ll address a variety of manufacturer developments, from contract pharmacy restrictions to manufacturer audits to proposed 340B rebate models. They end with a forecast of what to watch for in 2025
Thank you for listening to our podcast! Email us at 340BUnscripted@spendmend.com if you have any questions or topics that you want us to address!

Ep 58 | Sanofi 340B Credit Model

In this week’s episode, Greg and Rob cover the recent policy notice put out by Sanofi regarding a 340B credit model. They discuss how it compares to other proposed credit/rebate models, and more importantly how this one is unique.
In the intro, the guys recap developments in Washington D.C., as well as some updates in court action amongst HRSA, covered entities and manufacturers regarding audit activity.

Ep 57 | Post-Election Outcome & 340B Implications

In this episode, Greg and Rob are joined by Rodney Whitlock, healthcare policy expert, to discuss the recent 2024 election results.    They’ll discuss what the second Trump Administration might prioritize in terms of healthcare policy, how a Republican-controlled Congress will impact 340B legislation activity, and whether or not any developments coming out of the upcoming lame-duck session might be on the horizon for 340B providers.
In the intro, Greg and Rob catch up on a variety of topics, including J&J’s recently filed lawsuit against HRSA regarding rebate models, CMS final rules around inflation rebate penalties, and they share some anecdotes from recent HRSA audit activity.
 
Register for our upcoming webinars below:
340B Hidden Strategies: Mastering 340B Advocacy: https://attendee.gotowebinar.com/register/8182646241351674200?source=340B+Unscripted
 
The Power of Trulla: An Overview of Our Award-Winning Pharmacy Procurement Software: https://attendee.gotowebinar.com/register/8037692126057457751?source=340B+Unscripted
 

Ep 56 | 2024 General Election Outlook & 340B

In this episode, Greg and Rob are joined by Mike Strazzella, government affairs expert from Buchanan Ingersoll & Rooney, to discuss the upcoming general election, and what races may be critical to future 340B policy developments. They’ll discuss Senate and House races that could precipitate leadership changes in Congressional committees that drive legislative work, debate what a future Harris or Trump administration means for health care policy in general, and they wrap up with some conversation around how stakeholders can successfully advocate for the importance of the 340B Program.
Have a 340B question or topic you want us to cover?  Email us at 340BUnscripted@spendmend.com.

Ep 55 | All About 340B Modifiers

In this episode, Greg and Rob discuss the various uses of 340B billing modifiers. They’ll discuss some general considerations around what billing modifiers are used for, highlight differences between hospital/clinic and pharmacy billing in terms of applying correct modifiers, and debate different aspects of Medicaid and Medicare billing modifier requirements.  It’s another heavy duty 340B-operations focused episode.